The New Role of Blood Tests in Helping to Diagnose Alzheimer’s Disease

Lori La Bey talks with Dr. Braunstein the CEO and president of C₂N Diagnostics, a specialty diagnostics company with a vision to bring Clarity Through Innovation®. The company’s Precivity™ tests are innovative new blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease, and aid in medical management and treatment decisions.

Learn:

1. What is C2N Diagnostics working on?
2. What are the 3 types of Precivity tests?
3. How fast do the blood tests get turned around for results? 
4. Are all Precivity tests needed?
5. Is genetic counseling set up as support for those taking the APOE tests?
6. What is the cost-effectiveness of the Precivity tests compared to other tests such as MRIs and PET Scans?
7. Is there a financial assistance program for the Precivity tests?

Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast

https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432

Listen and Subscribe to Alzheimer’s Speaks on Spotify

https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3

Contact  C2N ADiagnostics

Website  www.precivityAD.com

X - Twitter  @C2NDiagnostics

Facebook  www.facebook.com/C2NDiagnostics

Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/

Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011.

Alzheimer's Speaks is part of the Senior Resource Podcast Network.